Take Action to Help More Minnesotans to Qualify for Minnesota’s Medical Cannabis Program and Find Relief!
Anxiety, sickle cell disease, and tic disorder are three conditions which negatively impact Minnesotan’s every year. During difficult and stressful times like the COVID-19 pandemic, more people are reporting increased levels of stress and social anxieties.
Join us in petitioning to expand the Medical Cannabis Program by adding anxiety, sickle cell disease, and tic disorder as qualifying conditions. Together, we can make a real difference and help many Minnesotans gain access to natural, plant-based medicine and the relief they need!
Research has shown that medical cannabis can reduce anxiety in patients suffering from other qualifying conditions, such as PTSD. While certified to treat other symptoms including chronic pain, inflammatory bowel disease or seizures, research found that secondary symptoms such as anxiety were often among the first symptoms to improve with use of medical cannabis. Improvements among patients being treated with medical cannabis are rarely accompanied by any side effects.
Please take 60 seconds to send an email pledging your support for expanding the Medical Cannabis Program’s list of qualifying conditions. And, if you feel comfortable doing so, please personalize your message so they understand why you feel so strongly about expanding the medical cannabis program. Submit your comments by Friday, Oct. 16.
Support for Each Proposed Qualifying Condition
Anxiety –Research has shown that medical cannabis can reduce anxiety in patients being treated for other qualifying conditions, such as chronic pain and cancer. A majority of older patients when surveyed report cannabis to be extremely or somewhat helpful for anxiety and additional research supports the reduction of benzodiazepine use in medical cannabis patients.
Sickle Cell Disease –Recent research supports the ability of medical cannabis to not only reduce pain associated with Sickle Cell Disease, but also to be a cost-effective alternative that could reduce hospital admissions.
Tic Disease – Both research and Vireo’s own anecdotal evidence of treating Minnesota patients with the State-approved qualifying condition, Tourette Syndrome, support the ability of cannabis to safely decrease the intensity of tics, as well as slow the tic urge, among other positive benefits. The health benefits from medical cannabis should be extended to patients who may not have a diagnosis of Tourette Syndrome, but suffer from the same debilitating symptoms.
“These three conditions merit consideration from the OMC, and we remain hopeful that Minnesota will expand its list of qualifying conditions,” said Dr. Sujit Varma, MD, a Minneapolis-based physician certified by the American Board of Psychiatry and Neurology. “Research has shown that medical cannabis can provide ample relief and serves as a safer alternative to traditional pharmaceuticals.”